Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariela Noy

Showing results (51-60 of 138) with videos related to

Pageof 14
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2009
Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantationTrudy N Small, Andrew D Zelenetz, Ariela Noy, et al.
Haematologica|February 29, 2020
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
JCO Global Oncology|July 8, 2020
Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 StudyRobert M Strother, Satish Gopal, Meg Wirth, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2018
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)Juan C Ramos, Joseph A Sparano, Michelle A Rudek, et al.
Blood|January 24, 2004
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaTarun Kewalramani, Andrew D Zelenetz, Stephen D Nimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNicole Lamanna, Joseph G Jurcic, Ariela Noy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047Alexandra M Levine, Ariela Noy, Jeannette Y Lee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 2016
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell LymphomaHeiko Schöder, Andrew D Zelenetz, Paul Hamlin, et al.
Leukemia & Lymphoma|May 31, 2012
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy ConsortiumUlas D Bayraktar, Juan Carlos Ramos, Adam Petrich, et al.
British Journal of Haematology|October 16, 2014
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantationDavid J Straus, Paul A Hamlin, Matthew J Matasar, et al.
Pageof 14

Showing results (51-60 of 138) with videos related to

Sort By:
Pageof 14
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2009
Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantationTrudy N Small, Andrew D Zelenetz, Ariela Noy, et al.
Haematologica|February 29, 2020
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
JCO Global Oncology|July 8, 2020
Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 StudyRobert M Strother, Satish Gopal, Meg Wirth, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2018
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)Juan C Ramos, Joseph A Sparano, Michelle A Rudek, et al.
Blood|January 24, 2004
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaTarun Kewalramani, Andrew D Zelenetz, Stephen D Nimer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNicole Lamanna, Joseph G Jurcic, Ariela Noy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047Alexandra M Levine, Ariela Noy, Jeannette Y Lee, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 2016
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell LymphomaHeiko Schöder, Andrew D Zelenetz, Paul Hamlin, et al.
Leukemia & Lymphoma|May 31, 2012
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy ConsortiumUlas D Bayraktar, Juan Carlos Ramos, Adam Petrich, et al.
British Journal of Haematology|October 16, 2014
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantationDavid J Straus, Paul A Hamlin, Matthew J Matasar, et al.
Pageof 14